Introduction
The prediction of arteriovenous fistula (AVF) outcomes remains a challenge for those involved in management of patients with end-stage renal disease (ESRD). Candidates for vascular access are drawn from a widely heterogeneous population varying in age, ethnicity, co-morbidities and cause of ESRD. Poor AVF outcomes can be the result of early thrombosis of the fistula or the failure to mature (FTM) after formation. FTM rates are high with large studies reporting that up the vessel but also play a part in medial wall smooth muscle proliferation and thickening leading to vessel stiffness.
Atherosclerotic and arteriosclerotic processes represent separate disease processes with atherosclerosis being a disease of the intima causing occlusive lesions and arteriosclerosis representing medial wall hypertrophy and hyperplasia of smooth muscle cells resulting in increased thickness and stiffness of the arterial wall (7, 8) . The highly distensible aorta and arterial tree deliver blood to the end organs and also buffer the potentially damaging peak and trough pressures produced by the cardiac cycle (9) . Arterial disease in the form of arteriosclerosis, atherosclerosis and pre-existing neointimal thickening associated with diabetes, hypertension and ESRD itself may contribute to the development of neointimal hyperplasia following AVF formation (10) . These changes in vessel structure and function have been reported to occur early in patients with ESRD, and vessel changes are seen early even in patients with mildly reduced glomerular filtration rate (GFR) (11) .
Aortic pulse-wave velocity (PWV) is currently considered to be the "gold-standard" measurement of arterial stiffness (12) . Measures derived from central pulse-wave analysis (central systolic pressure, pulse pressure and augmentation index) are considered indirect, surrogate markers of arterial stiffness. These markers have been shown to be powerful predictors of cardiovascular mortality and morbidity in patients with ESRD (13, 14) . There are several commercially available systems for measuring PWV; however, the Vicorder system requires relatively less training to become proficient in its use and is well tolerated by patients. Vicorder measurements typically have very good intra-and inter-observer reproducibility in a number of conditions and produce comparable results to those obtained using the widely used method of applanation tonometry (15) .
Advanced glycation end-products (AGEs) contribute to the pathophysiology of vascular disease where they accumulate in the endothelial cell wall and disrupt cellular structure and function including decreasing the bioavailability of nitrous oxide and alter endothelial cell surface structure from an anticoagulant to procoagulant state (16) . The AGE reader illuminates a 1 cm 2 area of skin on the forearm at a wavelength of 300-420 nm. Light is collected from the skin at the 300-600 nm range. Skin autofluorescence (AF) is automatically calculated as a mean of three measurements of the average light intensity per nanometer in the 420-600 nm range divided by the average light intensity per nanometer at the 300-420 nm range (17) . The measurement of AGEs offers an exciting new assessment tool and could help to select patients for therapeutic trials to reduce AGE levels with agents such as aminoguanidine, statins, pyridoxamine and dietary modifications.
The aim of this study was to assess the predictive value of non-invasive markers of arterial disease on the early postoperative AVF outcomes using an observational cohort study of ESRD patients assessed specifically for parameters of arterial disease.
Methods
The Renal Impairment In Secondary Care (RIISC) study is a prospective, observational cohort study in patients with chronic kidney disease (CKD) stage 4 and 5 or CKD stage 3 with accelerated renal failure progression and/or proteinuria (CKD stage 3 with either decline of eGFR ≥5 mL/min/ year or ≥10 mL/min/5years or albumin/creatinine ratio ≥70 mg/mmol on three occasions) (4) . Participants undergo a detailed bio-clinical assessment that includes measures of vascular health, periodontal health, quality of life and socioeconomic status, clinical assessment and collection of samples for biomarker analysis. The outcomes of interest include cardiovascular events, progression to ESRD and death. The cardiovascular assessments performed within this study offer a unique opportunity to follow a subgroup of ESRD patients through the AVF pathway and correlate these measurements with outcomes in the hope of identifying novel markers that predict short-and medium-term success or failure.
The study was approved by the South Birmingham Local Research Ethics committee (reference: 10/H1207/6) and all participants gave informed and written consent. The study was conducted in accordance with the Declaration of Helsinki. (Clinical Trials Registration Number: NCT01722383; Date of Registration: November 11, 2012).
All patients enrolled in the RIISC study were reviewed to assess whether they had been referred for AVF formation. We included all patients in whom an AVF had been performed after enrolment to the RIISC study. We correlated patient demographics, co-morbidities, peripheral and central blood pressure measurements, augmentation index and aortic PWV as recorded by the BP Tru (BPTru Medical Devices, Coquitlam, Canada) and Vicorder (Covidien, as part of Medtronic, Minneapolis, USA) and AGE reader (DiagnOptics, Groningen, The Netherlands) machines against the short-term AVF outcomes of sonographic patency at 6-week review. For the purposes of this study, primary failure (PFL) is defined as thrombosis at 6-week review. Primary patency (PPT) is defined as an AVF that had not thrombosed at 6-week review but has not yet been used for dialysis. Short-term outcomes were considered acceptable for this study since the majority of the arterial remodelling required to allow an AVF to mature occurs within 24 hours of AVF formation (18) . Each patient was included only once in the analysis to reduce the bias from multiple subsequent failures. Statistical analysis was performed using SPSS version 19 (SPSS Inc, Chicago, Il). Numerical values are expressed as mean± standard deviation or median (IQ range) for non-parametric data. Normality of the distribution of data was assessed using an inspection of the histogram and normal probability plot. Data were analysed using chi-squared test for categorical data and Student's t-test, Wilcoxon signed rank tests to analyse the data depending on normal or non-normal distribution. Binary logistic regression to assess predictive value of each of the parameters for inclusion in a predictive model of positive AVF outcomes.
The BP Tru machine records 6 measurements of blood pressure taken peripherally and calculates the mean of the last 5 measurements to yield a result that is comparable to the average 24-hour ambulatory blood pressure measurement. The Vicorder machine assesses peripheral and central blood pressure, performs pulse wave analysis to yield augmentation index and measures pulse wave velocity to reflect arterial stiffness. The faster the propagation of the wave through the aorta, the less buffering occurs and therefore, by inference, the stiffer the blood vessel is. Augmentation index represents the difference
Results
Analysis of collected data was performed in June 2015. At that time, there were 718 patients enrolled in the RIISC study. A total of 108 AVFs had been created in 86 patients (Fig. 1) . A synopsis of the types of AVF created and their outcomes is given in Table I . Mean duration between recruitment into the RIISC study and assessment for AVF creation was 22 months (0-48 months). We examined the first AVF attempt to exclude the confounding influence that multiple AVF failures would have on the results.
When comparing the demographics of the PPT group against PFL, the PPT group was found to have a significantly higher body mass index (BMI) (p = 0.01). There were no significant differences found in gender, age, prevalence of diabetes, ischaemic heart disease, peripheral vascular disease, chronic obstructive pulmonary disease, cerebrovascular disease, malignancy or history of smoking as shown in Table II .
The relationship between peripheral and central systolic and diastolic blood pressure, pulse pressure and mean arterial pressure as measured by the BP Tru and Vicorder devices is shown in Table III . Higher systolic and diastolic blood pressure measurements were recorded by each of the devices in the PFL group than the PPT group. The corresponding higher PFL at 6-week review (%) 24 (27.9)
PPT at 6-week review (%) 62 (72.1) PFL = primary failure; PPT = primary patency. between the second and first peaks of the central pressure waveform in systole, expressed as a percentage of the pulse pressure. The Vicorder measurements were performed with the patient semi-recumbent at 45 degrees with blood pressure cuffs around the arm and mid-thigh and an inflatable bladder over the carotid artery. A measurement of clavicle to mid-thigh region was taken to account for size differences between patients. All measurements were recorded within a 2°C room temperature fluctuation. The patients then had assessments of their AGE deposition in their skin using the AGE reader. Three measurements were taken sequentially and the mean recorded. pulses pressures and mean arterial pressures continue this trend as expected. Statistically significant differences were found in the diastolic blood pressure measurements taken by the BP Tru machine. Difference in preoperative vein intraluminal diameter was significant with the PPT having a larger venous diameter than the PFL group (p≤0.01); however, this was not true of arterial size (Tab. IV). Mean augmentation index and augmentation index 75, as measured by central arterial pulse wave analysis was significantly higher in the PPT group than the PFL group (p = 0.03 and 0.03, respectively) as shown in Table IV . Advanced glycation end-product (Tab. IV) measurements did not vary significantly between the PPT and PFL groups (p = 0.4). Aortic pulse wave velocity (Tab. IV) was slower in the PPT group than the PFL group (p = 0.32).
Logistic regression analysis was undertaken to generate and assess the value of a predictive model for short-term AVF outcome based on the factors which showed a correlation with outcome. Included in the analysis were all parameters that show a p value of less than 0.2. A predictive model was generated, which included BMI, diastolic blood pressure and 
Discussion
Relatively few studies have been performed to quantitatively and qualitatively assess markers of arterial disease prior to AVF formation. Studies focused on the downstream changes necessary for venous remodelling have highlighted many of the biological pathways that may be targets for therapy, although there has not yet been robust clinical translation of this research (19) .
The critical relationship between venous remodelling and arterial adaptation to permit AVF maturation is an important area to study in an effort to understand the pre-operative factors that predict AVF outcomes and to develop new therapies to improve AVF maturation. In the present study, there is evidence that arterial disease is a predictor for failure of AVF maturation. Current smokers and patients with diabetes, commonly known risk factors for arterial disease, have poorer AVF outcomes (20) . In elderly patients, the outcomes for more distal limb AVFs are poor, even if the venous vessels are of comparable size and quality to younger patients (21) . Diseases of the veins, beyond those iatrogenically induced by venepuncture, cannulation and central venous lines, are uncommon yet there has been a clinical emphasis on venous assessment and mapping rather than arterial assessment in overall AVF planning.
The aim of this study was to identify objective markers of arterial disease that affect AVF outcomes. Similar patient demographics were present in all three groups.
Aortic PWV was slower in the PPT group at 10.2 m/s compared to the PFL group 10.8 m/s. This difference was not (12) . Therefore, all patients in this ESRD cohort have significantly greater aortic stiffness, as measured by their PWV, compared to a healthy population. This is an important observation since all AVFs must undergo significant remodelling of both the artery and the vein in order to become mature. If all patients with ESRD show stiff vessels, then perhaps the deciding variable in eventual patency lies on the venous rather than the arterial side of the anastomosis. BMI was found to be significantly lower in the PPT group. This is contrary to evidence suggesting that BMI does not affect AVF outcomes (20) . Vasalotti and colleagues performed a prospective assessment of patients with a BMI >27 kg/m 2 versus those with a lower BMI and found no difference in the prevalence of a functioning AVF (22) . A larger vein intraluminal diameter was found in the PPT group at 3.6 mm versus 3.0 mm. A recent systematic review (23) has concluded that whilst the use of preoperative Doppler ultrasound (DUS) is associated with a higher rate of commencing dialysis on an AVF that this conclusion does not reach statistical significance and therefore novel predictors of outcomes may help to clarify factors leading to fistula success.
Whilst a large volume of data is available on the effect of arterial stiffness in predicting cardiovascular outcomes in ESRD (24, 25) , there is a relative paucity of evidence describing the effect arterial stiffness has on AVF outcomes. The use of generalised measures of arterial disease as used here may not have the specificity to define outcome of AVFs at a specific site. Arterial disease severity is often asymmetrical and a more detailed assessment of the actual brachial or radial artery may be required to be able to accurately predict AVF outcome.
The significance of augmentation index in this work is perplexing. Augmentation index is thought to rise with arterial stiffness and from data published from the RIISC study already looking at the effects of allopurinol on pulse wave velocity, no significant difference was found between patients with regard to augmentation index, whereas a significant difference was found in pulse wave velocity (26) . We found that a lower augmentation index is associated with a better chance of achieving a working AVF. This conclusion will require validation in another group of patients coming to AVF formation before it will be considered conclusive. Whilst many authors have suggested a positive correlation of augmentation index and pulse wave velocity (27) , others have suggested that they have no relationship to each other in certain circumstances (28) Kelly and colleagues have also examined the effects of vasoactive drugs on augmentation index and PWV and found that nitroglycerin significantly reduces augmentation index and angiotensin II significantly increases it whilst having minimal effect on PWV (29) .
Recently published data suggest that atenolol is superior to lisinopril in improving arterial stiffness (30) . The authors of this paper concede however that the improvement in aortic stiffness may be explained by the blood-pressure lowering effects of the drug. According to our results, reduction in blood pressure and increase in augmentation index may play a part in improving AVF outcomes. Having a higher BMI may be protective against PFL. Reducing aortic pulse wave velocity may also improve AVF outcomes; however, our results do not reach statistical significance in this parameter.
Limitations
The major limitation in this study is the time difference between initial recruitment into the RIISC study and the referral for AVF formation. There may have been changes to baseline haemodynamics related to the progression of ESRD and/or the introduction of medications that could have had an impact on the non-invasive markers of vascular disease. In addition, assessment of central arterial stiffness may be of limited correlation with the prediction of outcomes of a peripherally sited AVF. More localised assessment of brachial artery stiffness and endothelial response to vascular occlusion may provide improved predictive capacity. Further prospective trials with the pre-operative assessments closer to the time of AVF formation would permit more robust correlations to be made between these vascular biomarkers and AVF outcomes.
Conclusion
Arterial disease, and in particular arteriosclerotic processes leading to arterial stiffening, are likely to play an important part in reducing the ability of the artery to adapt and undergo changes necessary for AVF maturation. The data presented here are not robust enough to explain AVF failure from arterial stiffness alone. Further studies to examine the correlation between arterial stiffness measurements, particularly at discrete local sites, accompanied by endothelial functional measurements are essential to determine if these parameters are clinically valuable in predicting fistula outcomes for patients referred for AVF procedures.
Disclosures
Financial support: The study is supported by JABBS foundation (Birmingham, United Kingdom) (URL: http://opencharities.org/ charities/1128402), University Hospital Birmingham Charities (URL: http://qehb.org/) and the British Renal Society (URL: http://www. britishrenal.org/). Conflict of interest: None of the authors has financial interest related to this study to disclose.
